Codexis Takes a Bold Step Forward with New Facility
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions, has recently made an exciting advancement in its operations. The company has signed a lease for a new GMP manufacturing facility, which spans 34,000 square feet. This new space, located in an area designated for biotech development, will enhance Codexis’s capabilities significantly.
Enhanced Manufacturing Capabilities
This state-of-the-art facility is designed to support the GMP manufacturing of small interfering RNA (siRNA) and other oligonucleotides. Codexis plans to initiate modifications to the space early in the coming year, aiming to tailor it for optimal production efficiency. Furthermore, the facility's design will also support the scaling up of high-quality purified enzymes, which are essential components of the company’s ECO Synthesis platform.
CEO's Vision for the Future
Alison Moore, PhD, President and CEO of Codexis, shared her enthusiasm for this development. She stated, "This facility marks a fundamental pivot in Codexis’s transformation into a development partner of choice for enzymatic manufacturing of oligonucleotides. This facility will allow us to offer manufacturing services to our customers to support early clinical trials, and underscores our commitment to changing how siRNA is made while delivering the highest levels of quality and service. Furthermore, the flexibility of the facility will allow us to adapt it to match the evolving needs of our business."
About Codexis and Its Innovative Solutions
Codexis is recognized for its commitment to finding solutions in the manufacturing of therapeutics. The company works diligently to leverage its proprietary CodeEvolver technology platform to discover and develop high-performance enzymes. These enzymes help to tackle real-life challenges in the production of small-molecule pharmaceuticals and nucleic acid synthesis.
Advancing RNAi Therapeutics
Currently, Codexis is focused on the development of its ECO Synthesis manufacturing platform. This innovative approach seeks to implement enzymatic methods for the large-scale production of RNAi therapeutics. By utilizing unique enzymes, Codexis can enhance yield, reduce energy usage, and minimize waste during manufacturing processes—all crucial factors in today’s competitive landscape.
Commitment to Quality and Collaboration
With the new facility, Codexis is not just expanding its operational footprint; it is also reinforcing its commitment to quality. The company aims to work closely with partners and clients throughout early clinical trials, ensuring that the manufacturing process can adapt to meet the growing demands for high-quality therapeutics. This step forward highlights Codexis's dedication to excellence in the field of oligonucleotide manufacturing.
Contact Information for Further Inquiries
For investors and potential partners interested in learning more about Codexis, the company has made it easy to reach out. Georgia Erbez is the point of contact and can be reached at (650) 421-8100 or via email at ir@codexis.com. Codexis welcomes discussions about its innovative technologies and partnerships that can enhance therapeutic development.
Frequently Asked Questions
What is the significance of Codexis's new GMP facility?
The new GMP facility will significantly enhance Codexis's capabilities in manufacturing RNA therapeutics, allowing them to meet the demands of clinical trials.
What can we expect from Codexis in the upcoming years?
Codexis plans to expand its operations and improve manufacturing technology to better serve the biotechnology sector, particularly in RNA applications.
Who can I contact for investor relations at Codexis?
Georgia Erbez is the investor contact and can be reached at (650) 421-8100 or via email at ir@codexis.com.
What kind of enzymes does Codexis specialize in?
Codexis specializes in high-performance enzymes that facilitate the manufacturing of small molecules and nucleic acids, focusing on efficiency and sustainability.
How does the ECO Synthesis platform work?
The ECO Synthesis platform utilizes enzymatic methods to produce RNAi therapeutics, which provides benefits like improved yield and reduced energy use.
